GlassScriptPhysician profile
Peter Szoke
NPI 1851491328
$13,126.35
in general payments reported to CMS, 2019-2025
61 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,350 · 2020: $1,563 · 2021: $2,317 · 2022: $1,781 · 2023: $1,870 · 2024: $1,896 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,115.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,488.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,238.37 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $1,177.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $961.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $855.02 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $709.47 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $682.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $454.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $396.64 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $395.83 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $394.37 | 2019-2024 | |
| Esperion Therapeutics, INC. | $346.96 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $328.82 | 2019-2025 | Xarelto, Spravato |
| Antares Pharma, INC. | $280.22 | 2019-2024 | Xyosted |
| Portola Pharmaceuticals, LLC | $270.06 | 2019-2020 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Szoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.